A unique type of GSK-3 inhibitor brings new opportunities to the clinic

Science Signaling

Volumn 9, Issue 454, 2016, Pages

  Licht Murava, Avital ^a   Paz, Rom ^a   Vaks, Lilach ^a   Avrahami, Limor ^a   Plotkin, Batya ^a   Eisenstein, Miriam ^b   Eldar Finkelman, Hagit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BETA CATENIN; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN RECEPTOR SUBSTRATE 1; L 803; L 807; PEPTIDE; PROTEIN P62; TYROSINE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALYSIS; COGNITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STABILITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEAR CONDITIONING TEST; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MEMORY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOCIAL INTERACTION; STATE DEPENDENT LEARNING; STATIC ELECTRICITY; SYMPTOM; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; DISEASE MODEL; ENZYMOLOGY; HUMAN; MALE; METABOLISM;

ALZHEIMER DISEASE; ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MICE; PEPTIDES;

EID: 84995775643     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aah7102     Document Type: Article

References (83)

1. G. Manning, D. B. Whyte, R. Martinez, T. Hunter, S. Sudarsanam, The protein kinase complement of the human genome. Science 298, 1912-1934 (2002).
2. J. Bain, H. McLauchlan, M. Elliott, P. Cohen, The specificities of protein kinase inhibitors: An update. Biochem. J. 371, 199-204 (2003).
3. J. Bain, L. Plater, M. Elliott, N. Shpiro, C. J. Hastie, H. McLauchlan, I. Klevernic, J. S. Arthur, D. R. Alessi, P. Cohen, The selectivity of protein kinase inhibitors: A further update. Biochem. J. 408, 297-315 (2007).
4. S. K. Hanks, A. M. Quinn, T. Hunter, The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. Science 241, 42-52 (1988).
5. S. S. Taylor, E. Radzio-Andzelm, T. Hunter, How do protein kinases discriminate between serine/threonine and tyrosine Structural insights from the insulin receptor proteintyrosine kinase. FASEB J. 9, 1255-1266 (1995).
6. B. E. Kemp, R. B. Pearson, C. M. House, Pseudosubstrate-based peptide inhibitors. Methods Enzymol. 201, 287-304 (1991).
7. T. R. Soderling, Protein kinases. Regulation by autoinhibitory domains. J. Biol. Chem. 265, 1823-1826 (1990).
8. T. Eichholtz, D. B. A. de Bont, J. de Widt, R. M. J. Liskamp, H. L. Ploegh, A myristoylated pseudosubstrate peptide, a novel protein kinase C inhibitor. J. Biol. Chem. 268, 1982-1986 (1993).
9. D. A. Brickey, J. G. Bann, Y.-L. Fong, L. Perrino, R. G. Brennan, T. R. Soderling, Mutational analysis of the autoinhibitory domain of calmodulin kinase II. J. Biol. Chem. 269, 29047-29054 (1994).
10. C. T. Wlash, Suicide substrates, mechanism-based inactivators: Recent developments. Annu. Rev. Biochem. 53, 493-535 (1984).
11. H. Eldar-Finkelman, A. Martinez, GSK-3 inhibitors: Preclinical and clinical focus on CNS. Front. Mol. Neurosci. 4, 32 (2011).
12. M. K. King, M. Pardo, Y. Cheng, K. Downey, R. S. Jope, E. Beurel, Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments. Pharmacol. Ther. 141, 1-12 (2014).
13. M. Llorens-Martin, J. Jurado, F. Hernández, J. Ávila, GSK-3b, a pivotal kinase in Alzheimer disease. Front. Mol. Neurosci. 7, 46 (2014).
14. S. H. Liang, J. M. Chen, M. D. Normandin, J. S. Chang, G. C. Chang, C. K. Taylor, P. Trapa, M. S. Plummer, K. S. Para, E. L. Conn, L. Lopresti-Morrow, L. F. Lanyon, J. M. Cook, K. E. G. Richter, C. E. Nolan, J. B. Schachter, F. Janat, Y. Che, V. Shanmugasundaram, B. A. Lefker, B. E. Enerson, E. Livni, L. Wang, N. J. Guehl, D. Patnaik, F. F. Wagner, R. Perlis, E. B. Holson, S. J. Haggarty, G. El Fakhri, R. G. Kurumbail, N. Vasdev, Discovery of a highly selective glycogen synthase kinase-3 inhibitor (PF-04802367) that modulates tau phosphorylation in the brain: Translation for PET neuroimaging. Angew. Chem. Int. Ed. Engl. 55, 9601-9605 (2016).
15. F. F. Wagner, J. A. Bishop, J. P. Gale, X. Shi, M. Walk, J. Ketterman, D. Patnaik, D. Barker, D. Walpita, A. J. Campbell, S. Nguyen, M. Lewis, L. Ross, M. Weïwer, W. F. An, A. R. Germain, P. P. Nag, S. Metkar, T. Kaya, S. Dandapani, D. E. Olson, A.-L. Barbe, F. Lazzaro, J. R. Sacher, J. H. Cheah, D. Fei, J. Perez, B. Munoz, M. Palmer, K. Stegmaier, S. L. Schreiber, E. Scolnick, Y.-L. Zhang, S. J. Haggarty, E. B. Holson, J. Q. Pan, Inhibitors of glycogen synthase kinase 3 with exquisite kinome-wide selectivity and their functional effects. ACS Chem. Biol. 11, 1952-1963 (2016).
16. J. R. Woodgett, Molecular cloning and expression of glycogen synthase kinase-3/factorA. EMBO J. 9, 2431-2438 (1990).
17. D. P. Hanger, K. Hughes, J. R. Woodgett, J.-P. Brion, B. H. Anderton, Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett. 147, 58-62 (1992).
18. T. Li, C. Hawkes, H. Y. Qureshi, S. Kar, H. K. Paudel, Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3b. Biochemistry 45, 3134-3145 (2006).
19. M. G. Spillantini, M. Goedert, Tau pathology and neurodegeneration. Lancet Neurol. 12, 609-622 (2013).
20. M. R. Khanna, J. Kovalevich, V. M.-Y. Lee, J. Q. Trojanowski, K. R. Brunden, Therapeutic strategies for the treatment of tauopathies: Hopes and challenges. Alzheimers Dement. 12, 1051-1065 (2016).
21. S. Ikeda, S. Kishida, H. Yamamoto, H. Murai, S. Koyama, A. Kikuchi, Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3b and b-catenin and promotes GSK-3b-dependent phosphorylation of b-catenin. EMBO J. 17, 1371-1384 (1998).
22. C. Yost, M. Torres, J. R. Miller, E. Huang, D. Kimelman, R. T. Moon, The axis-inducing activity, stability, and subcellular distribution of b-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 10, 1443-1454 (1996).
23. K. P. Hoeflich, J. Luo, E. A. Rubie, M.-S. Tsao, O. Jin, J. R. Woodgett, Requirement for glycogen synthase kinase-3b in cell survival and NF-kB activation. Nature 406, 86-90 (2000).
24. K. A. Steinbrecher, W. Wilson III, P. C. Cogswell, A. S. Baldwin, Glycogen synthase kinase 3b functions to specify gene-specific, NF-kB-dependent transcription. Mol. Cell. Biol. 25, 8444-8455 (2005).
25. M. Martin, K. Rehani, R. S. Jope, S. M. Michalek, Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 6, 777-784 (2005).
26. A. V. Ougolkov, M. E. Fernandez-Zapico, D. N. Savoy, R. A. Urrutia, D. D. Billadeau, Glycogen synthase kinase-3b participates in nuclear factor kB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. 65, 2076-2081 (2005).
27. I. Azoulay-Alfaguter, R. Elya, L. Avrahami, A. Katz, H. Eldar-Finkelman, Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cells growth. Oncogene 34, 4613-4623 (2015).
28. L. Avrahami, D. Farfara, M. Shaham-Kol, R. Vassar, D. Frenkel, H. Eldar-Finkelman, Inhibition of glycogen synthase kinase-3 ameliorates b-amyloid pathology and restores lysosomal acidification and mTOR activity in the Alzheimer's disease mouse model: In vivo and in vitro studies. J. Biol. Chem. 288, 1295-1306 (2013).
29. A. V. Franklin, M. K. King, V. Palomo, A. Martinez, L. L. McMahon, R. S. Jope, Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice. Biol. Psychiatry 75, 198-206 (2014).
30. E. Beurel, O. Kaidanovich-Beilin, W.-I. Yeh, L. Song, V. Palomo, S. M. Michalek, J. R. Woodgett, L. E. Harrington, H. Eldar-Finkelman, A. Martinez, R. S. Jope, Regulation of Th1 cells and experimental autoimmune encephalomyelitis by glycogen synthase kinase-J. Immunol. 190, 5000-5011 (2013).
31. P. T. T. Ly, Y. Wu, H. Zou, R. Wang, W. Zhou, A. Kinoshita, M. Zhang, Y. Yang, F. Cai, J. Woodgett, W. Song, Inhibition of GSK3b-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J. Clin. Invest. 123, 224-235 (2013).
32. L. Serenó, M. Coma, M. Rodríguez, P. Sánchez-Ferrer, M. B. Sánchez, I. Gich, J. M. Agulló, M. Pérez, J. Avila, C. Guardia-Laguarta, J. Clarimón, A. Lleó, T. Gómez-Isla, A novel GSK-3b inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol. Dis. 35, 359-367 (2009).
33. T. Engel, F. Hernández, J. Avila, J. J. Lucas, Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J. Neurosci. 26, 5083-5090 (2006).
34. J. Carmichael, K. L. Sugars, Y. P. Bao, D. C. Rubinsztein, Glycogen synthase kinase-3b inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J. Biol. Chem. 277, 33791-33798 (2002).
35. J. Avila, F. Wandosell, F. Hernández, Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors. Expert Rev. Neurother. 10, 703-710 (2010).
36. C. Hooper, R. Killick, S. Lovestone, The GSK3 hypothesis of Alzheimer's disease. J. Neurochem. 104, 1433-1439 (2008).
37. D. E. Hurtado, L. Molina-Porcel, J. C. Carroll, C. MacDonald, A. K. Aboagye, J. Q. Trojanowski, V. M.-Y. Lee, Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease. J. Neurosci. 32, 7392-7402 (2012).
38. B. Plotkin, O. Kaidanovich, I. Talior, H. Eldar-Finkelman, Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J. Pharmacol. Exp. Ther. 305, 974-980 (2003).
39. C. J. Fiol, A. M. Mahrenholz, Y. Wang, R. W. Roeske, P. J. Roach, Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J. Biol. Chem. 262, 14042-14048 (1987).
40. J. R. Woodgett, P. Cohen, Multisite phosphorylation of glycogen synthase. Molecular basis for the substrate specificity of glycogen synthase kinase-3 and casein kinase-II (glycogen synthase kinase-5). Biochim. Biophys. Acta 788, 339-347 (1984).
41. B. Chu, F. Soncin, B. D. Price, M. A. Stevenson, S. K. Calderwood, Sequential phosphorylation by mitogen-activated protein kinase and glycogen synthase kinase 3 represses transcriptional activation by heat shock factor-1. J. Biol. Chem. 271, 30847-30857 (1996).
42. O. Kaidanovich-Beilin, H. Eldar-Finkelman, Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: Molecular characterization in liver and muscle. J. Pharmacol. Exp. Ther. 316, 17-24 (2006).
43. R. Rao, C.-M. Hao, R. Redha, D. H. Wasserman, O. P. McGuinness, M. D. Breyer, Glycogen synthase kinase 3 inhibition improves insulin-stimulated glucose metabolism but not hypertension in high-fat-fed C57BL/6J mice. Diabetologia 50, 452-460 (2007).
44. O. Kaidanovich-Beilin, A. Milman, A. Weizman, C. G. Pick, H. Eldar-Finkelman, Rapid anti-depressive like activity of specific glycogen synthase kinase-3 inhibitor, and its effect on b-catenin in the mouse hippocampus. Biol. Psychiatry 55, 781-784 (2004).
45. Q. Zhu, J. Yang, S. Han, J. Liu, J. Holzbeierlein, J. B. Thrasher, B. Li, Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate 71, 835-845 (2011).
46. G. Chen, K. A. Bower, C. Ma, S. Fang, C. J. Thiele, J. Luo, Glycogen synthase kinase 3b (GSK3b) mediates 6-hydroxydopamine-induced neuronal death. FASEB J. 18, 1162-1164 (2004).
47. A. Licht-Murava, B. Plotkin, M. Eisenstein, H. Eldar-Finkelman, Elucidating substrate and inhibitor binding sites on the surface of GSK-3b and the refinement of a competitive inhibitor. J. Mol. Biol. 408, 366-378 (2011).
48. R. Ilouz, N. Kowelsman, M. Eisenstein, H. Eldar-Finkelman, Identification of novel glycogen synthase kinase-3b substrate-interacting residues suggests a common mechanism for substrate recognition. J. Biol. Chem. 281, 30621-30630 (2006).
49. Z. Liberman, H. Eldar-Finkelman, Serine 332 phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 attenuates insulin signaling. J. Biol. Chem. 280, 4422-4428 (2005).
50. R. Dajani, E. Fraser, S. M. Roe, N. Young, V. Good, T. C. Dale, L. H. Pearl, Crystal structure of glycogen synthase kinase 3b: Structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 105, 721-732 (2001).
51. E. ter Haar, J. T. Coll, D. A. Austen, H.-M. Hsiao, L. Swenson, J. Jain, Structure of GSK3b reveals a primed phosphorylation mechanism. Nat. Struct. Biol. 8, 593-596 (2001).
52. B. Rubinfeld, I. Albert, E. Porfiri, C. Fiol, S. Munemitsu, P. Polakis, Binding of GSK3b to the APCb-catenin complex and regulation of complex assembly. Science 272, 1023-1026 (1996).
53. A. Herreman, G. Van Gassen, M. Bentahir, O. Nyabi, K. Craessaerts, U. Mueller, W. Annaert, B. De Strooper, g-Secretase activity requires the presenilin-dependent trafficking of nicastrin through the Golgi apparatus but not its complex glycosylation. J. Cell Sci. 116, 1127-1136 (2003).
54. J.-H. Lee, W. H. Yu, A. Kumar, S. Lee, P. S. Mohan, C. M. Peterhoff, D. M. Wolfe, M. Martinez-Vicente, A. C. Massey, G. Sovak, Y. Uchiyama, D. Westaway, A. M. Cuervo, R. A. Nixon, Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 141, 1146-1158 (2010).
55. J. Born, T. Lange, W. Kern, G. P. McGregor, U. Bickel, H. L. Fehm, Sniffing neuropeptides: A transnasal approach to the human brain. Nat. Neurosci. 5, 514-516 (2002).
56. L. Illum, Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 11, 1-18 (2000).
57. T. Li, H. K. Paudel, Glycogen synthase kinase 3b phosphorylates Alzheimer's diseasespecific Ser396 of microtubule-associated protein tau by a sequential mechanism. Biochemistry 45, 3125-3133 (2006).
58. D. P. Hanger, B. H. Anderton, W. Noble, Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 15, 112-119 (2009).
59. H. Rosenmann, N. Grigoriadis, H. Eldar-Levy, A. Avital, L. Rozenstein, O. Touloumi, L. Behar, T. Ben-Hur, Y. Avraham, E. Berry, M. Segal, I. Ginzburg, O. Abramsky, A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Exp. Neurol. 212, 71-84 (2008).
60. H. Oakley, S. L. Cole, S. Logan, E. Maus, P. Shao, J. Craft, A. Guillozet-Bongaarts, M. Ohno, J. Disterhoft, L. Van Eldik, R. Berry, R. Vassar, Intraneuronal b-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. J. Neurosci. 26, 10129-10140 (2006).
61. M. Leger, A. Quiedeville, V. Bouet, B. Haelewyn, M. Boulouard, P. Schumann-Bard, T. Freret, Object recognition test in mice. Nat. Protoc. 8, 2531-2537 (2013).
62. R. A. Bevins, J. Besheer, Object recognition in rats and mice: A one-trial non-matching-tosample learning task to study 'recognition memory'. Nat. Protoc. 1, 1306-1311 (2006).
63. G. Cipriani, M. Vedovello, M. Ulivi, A. Nuti, C. Lucetti, Repetitive and stereotypic phenomena and dementia. Am. J. Alzheimers Dis. Other Demen. 28, 223-227 (2013).
64. M. Langen, M. J. H. Kas, W. G. Staal, H. van Engeland, S. Durston, The neurobiology of repetitive behavior: Of mice. Neurosci. Biobehav. Rev. 35, 345-355 (2011).
65. M. A. Mines, C. J. Yuskaitis, M. K. King, E. Beurel, R. S. Jope, GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PLOS ONE 5, e9706 (2010).
66. C. J. Yuskaitis, M. A. Mines, M. K. King, J. D. Sweatt, C. A. Miller, R. S. Jope, Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem. Pharmacol. 79, 632-646 (2010).
67. O. Kaidanovich-Beilin, T. V. Lipina, K. Takao, M. van Eede, S. Hattori, C. Laliberté, M. Khan, K. Okamoto, J. W. Chambers, P. J. Fletcher, K. MacAulay, B. W. Doble, M. Henkelman, T. Miyakawa, J. Roder, J. R. Woodgett, Abnormalities in brain structure and behavior in GSK-3alpha mutant mice. Mol. Brain 2, 35 (2009).
68. J. J. Nadler, S. S. Moy, G. Dold, D. Trang, N. Simmons, A. Perez, N. B. Young, R. P. Barbaro, J. Piven, T. R. Magnuson, J. N. Crawley, Automated apparatus for quantitation of social approach behaviors in mice. Genes Brain Behav. 3, 303-314 (2004).
69. J. N. Crawley, T. Chen, A. Puri, R. Washburn, T. L. Sullivan, J. M. Hill, N. B. Young, J. J. Nadler, S. S. Moy, L. J. Young, H. K. Caldwell, W. S. Young, Social approach behaviors in oxytocin knockout mice: Comparison of two independent lines tested in different laboratory environments. Neuropeptides 41, 145-163 (2007).
70. D. J. Selkoe, Alzheimer's disease: Genes, proteins, and therapy. Physiol. Rev. 81, 741-766 (2001).
71. B. De Strooper, Proteases and proteolysis in Alzheimer disease: A multifactorial view on the disease process. Physiol. Rev. 90, 465-494 (2010).
72. J. Hardy, The amyloid hypothesis for Alzheimer's disease: A critical reappraisal. J. Neurochem. 110, 1129-1134 (2009).
73. R. A. Nixon, The role of autophagy in neurodegenerative disease. Nat. Med. 19, 983-997 (2013).
74. D. C. Rubinsztein, P. Codogno, B. Levine, Autophagy modulation as a potential therapeutic target for diverse diseases. Nat. Rev. Drug Discov. 11, 709-730 (2012).
75. D. Klionsky, An overview of autophagy: Morphology, mechanism and regulation. Antioxid. Redox Signal, (2013).
76. D. A. DeWitt, G. Perry, M. Cohen, C. Doller, J. Silver, Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease. Exp. Neurol. 149, 329-340 (1998).
77. B. Webster, L. Hansen, A. Adame, L. Crews, M. Torrance, L. Thal, E. Masliah, Astroglial activation of extracellular-regulated kinase in early stages of Alzheimer disease. J. Neuropathol. Exp. Neurol. 65, 142-151 (2006).
78. A. M. Birch, The contribution of astrocytes to Alzheimer's disease. Biochem. Soc. Trans. 42, 1316-1320 (2014).
79. M. M. Tirion, Large amplitude elastic Motions in proteins from a single-parameter, atomic analysis. Phys. Rev. Lett. 77, 1905-1908 (1996).
80. K. Suhre, Y.-H. Sanejouand, ElNémo: A normal mode web server for protein movement analysis and the generation of templates for molecular replacement. Nucleic Acids Res. 32, W610-W614 (2004).
81. D. Van Der Spoel, E. Lindahl, B. Hess, G. Groenhof, A. E. Mark, H. J. C. Berendsen, GROMACS: Fast, flexible, and free. J. Comput. Chem. 26, 1701-1718 (2005).
82. E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, E. C. Meng, T. E. Ferrin, UCSF Chimera-A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 (2004).
83. M. Ohno, L. Chang, W. Tseng, H. Oakley, M. Citron, W. L. Klein, R. Vassar, J. F. Disterhoft, Temporal memory deficits in Alzheimer's mouse models: Rescue by genetic deletion of BACE1. Eur. J. Neurosci. 23, 251-260 (2006).